PH12022550261A1 - Methods for preventing dengue and hepatitis a - Google Patents

Methods for preventing dengue and hepatitis a

Info

Publication number
PH12022550261A1
PH12022550261A1 PH1/2022/550261A PH12022550261A PH12022550261A1 PH 12022550261 A1 PH12022550261 A1 PH 12022550261A1 PH 12022550261 A PH12022550261 A PH 12022550261A PH 12022550261 A1 PH12022550261 A1 PH 12022550261A1
Authority
PH
Philippines
Prior art keywords
dengue
hepatitis
tdv
methods
preventing dengue
Prior art date
Application number
PH1/2022/550261A
Other languages
English (en)
Inventor
Derek Wallace
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/561,953 external-priority patent/US11590221B2/en
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of PH12022550261A1 publication Critical patent/PH12022550261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PH1/2022/550261A 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a PH12022550261A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IDP00201907241 2019-08-16
US16/561,953 US11590221B2 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
EP19195692.9A EP3620174B1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2019/049749 WO2020051334A1 (en) 2018-09-05 2019-09-05 Dengue vaccine unit dose and administration thereof
PCT/US2020/020991 WO2021034349A1 (en) 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a

Publications (1)

Publication Number Publication Date
PH12022550261A1 true PH12022550261A1 (en) 2023-06-26

Family

ID=74660757

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550261A PH12022550261A1 (en) 2019-08-16 2020-03-04 Methods for preventing dengue and hepatitis a

Country Status (10)

Country Link
EP (1) EP4013451A1 (cg-RX-API-DMAC7.html)
JP (2) JP7731344B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220049023A (cg-RX-API-DMAC7.html)
CN (1) CN114555113A (cg-RX-API-DMAC7.html)
AU (3) AU2020331884B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001476A2 (cg-RX-API-DMAC7.html)
CA (1) CA3147807A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022001742A (cg-RX-API-DMAC7.html)
PH (1) PH12022550261A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021034349A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260167703A1 (en) * 2022-11-02 2026-06-18 Takeda Vaccines, Inc. A method for determining the infectivity of a virus

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
AU2003239932A1 (en) 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
DK2054428T3 (da) 2006-08-15 2013-08-26 Government Of The U S A As Repr By The Secretary Dept Of Health & Human Services The Nat Inst Of Hea Udvikling af bestanddele til denque-virus-vaccine
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
EP3316905A1 (en) * 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
JP2019511533A (ja) * 2016-04-13 2019-04-25 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
TWI766876B (zh) 2016-08-03 2022-06-11 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法

Also Published As

Publication number Publication date
AU2026202847A1 (en) 2026-05-07
WO2021034349A1 (en) 2021-02-25
JP2022544613A (ja) 2022-10-19
JP2025032070A (ja) 2025-03-11
AU2020331884B2 (en) 2025-01-23
KR20220049023A (ko) 2022-04-20
AU2025202876B2 (en) 2026-01-29
MX2022001742A (es) 2022-04-07
EP4013451A1 (en) 2022-06-22
CN114555113A (zh) 2022-05-27
BR112022001476A2 (pt) 2023-10-03
CA3147807A1 (en) 2021-02-25
AU2020331884A1 (en) 2022-03-03
AU2025202876A1 (en) 2025-07-03
JP7731344B2 (ja) 2025-08-29

Similar Documents

Publication Publication Date Title
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112018005454A2 (pt) administração de potencializadores de cftr deuterados
JOP20170045B1 (ar) مركبات بيريدون رباعية الحلقة كمضادات فيروسية
PH12018550201A1 (en) Hepatitis b antiviral agents
MY169275A (en) Method of immunization against the four serotypes of dengue
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
UA124347C2 (uk) Циклічна динуклеотидна сполука
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MY202109A (en) Viral replication inhibitors
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MY194294A (en) Novel viral replication inhibitors
MX2009003417A (es) Metodo de inmunizacion contra los 4 serotipos de dengue.
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
SA520420261B1 (ar) تركيبات إرنوماب واستخداماتها
MX2022006742A (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter.
PH12015502128A1 (en) Novel dosing regimens of celgosivir for the treatment of dengue
PE20171061A1 (es) Composiciones farmaceuticas de accion prolongada para hepatitis c
MX2022001742A (es) Metodos para prevenir el dengue y la hepatitis a.
MX2022006414A (es) Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar.